Global Markets for Enzyme Inhibitors -- Focus on the US
- The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
- The U.S. market for enzyme inhibitors reached $46.8 billion in 2010 and came down to $44.9 billion in 2011. The market is expected to reach $47.4 billion by 2016, a CAGR of 1.1%.
- The kinase inhibitors market reached $10.8 billion in 2010 and came down to $10.4 billion in 2011. The market is expected to reach $11.6 billion by 2016, a CAGR of 2.2%.
STUDY GOALS AND OBJECTIVES
The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.
This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.
A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.
Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THE STUDY
Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.
Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.
SCOPE OF REPORT
The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
METHODOLOGY AND INFORMATION SOURCES
BCC conducted a comprehensive literature search, which included technical newsletters and journals. The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Subscribe to any of BCC Research’s many industry newsletters.
- Read announcements of recently published reports and newly launched newsletters.
- Register for its well-known conferences.
- Request additional information on any BCC research product.
- Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
Frequently Asked Questions (FAQs)
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.